Considering that LNPs can significantly enhance drug bioavailability through ApoE-mediated hepatic targeting,40 subsequent experiments employed LNP encapsulation to optimise RSV delivery efficiency, providing novel insights into NAFLD therapy. The gene discussed is APOE; the disease is metabolic dysfunction-associated steatotic liver disease.